Anti-apoptotic activity of ET<sub>B</sub> receptor agonist, IRL-1620, protects neural cells in rats with cerebral ischemia

Seema Briyal<sup>1</sup>, Amarendra K. Ranjan<sup>1</sup>, Mary G. Hornick<sup>1</sup>, Anupama K. Puppala<sup>1</sup>, Thanh Luu<sup>2</sup> & Anil Gulati<sup>1,3</sup>

Endothelin-B receptor agonist, IRL-1620, provides significant neuroprotection following cerebral ischemia in rats. Whether this neuroprotection is due to inhibition of apoptosis is unknown. IRL-1620-treated rats following permanent middle cerebral artery occlusion (MCAO) showed significant improvement in neurological and motor functions along with a decrease in infarct volume at 24 h (−81.3%) and day 7 (−73.0%) compared to vehicle group. Cerebral blood flow (CBF) significantly improved in IRL-1620-treated animals compared to vehicle by day 7 post MCAO. IRL-1620-treated rats showed an increase in phospho-Akt and decrease in Bad level 7 h post-occlusion compared to vehicle, while Akt and Bad expression was similar in cerebral hemispheres at 24 h post-MCAO. The phospho-Bad level was lower in vehicle- but not in IRL-1620-treated rats at 24 h. Anti-apoptotic Bcl-2 expression decreased, while pro-apoptotic Bax expression increased in vehicle-treated MCAO rats, these changes were attenuated (\(P<0.01\)) by IRL-1620. Mitochondrial membrane-bound Bax intensity significantly decreased in IRL-1620 compared to vehicle-treated MCAO rats. IRL-1620 treatment reduced (\(P<0.001\)) the number of TUNEL-positive cells compared to vehicle at 24 h and day 7 post MCAO. The results demonstrate that IRL-1620 is neuroprotective and attenuates neural damage following cerebral ischemia in rats by increasing CBF and reducing apoptosis.

Ischemic stroke is a significant worldwide health issue that can lead to serious long-term disability<sup>4</sup>. The pathophysiology behind ischemic stroke is multivariate and complex; therefore, developing an effective treatment capable of targeting multiple pathways is challenging. Prevention of apoptosis and restoration of blood flow are among the most important strategies, which could be target for treatment of ischemic stroke. Hence, a molecule or signaling pathway connected to neural cell survival/anti-apoptosis as well as blood perfusion would be an appropriate target. Since endothelin system is involved in the regulation of vascular tone as well as cell proliferation, survival and differentiation<sup>5,6</sup>, it may be an important target to treat stroke.

Endothelin (ET), an endogenous 21 amino acid peptide, produces its biological effects through activation of G-protein-coupled receptors: ET<sub>A</sub> and ET<sub>B</sub><sup>6,7</sup>. Interestingly, the expression of endothelin B (ET<sub>B</sub>) receptor has been observed on vascular cells as well as neural cells in the central nervous system (CNS) and plays important roles in cell survival and proliferation<sup>8-12</sup>. Moreover, the role of ET<sub>A</sub> receptors in the development of the CNS has been demonstrated by using homozygous ET<sub>B</sub> receptor deficient rats (spotting lethal rats, sl/sl) and a transgenic ET<sub>B</sub> receptor deficient rescue rats in prenatal and postnatal stages, respectively<sup>9,13,14</sup>. CNS disturbances and fatal birth defects are noted when ET<sub>A</sub> receptors are deficient or absent during the prenatal period. ET<sub>B</sub>-deficient rats have been shown to present with a decrease in neuronal progenitors and an increase in apoptosis within the dentate gyrus and cerebellum<sup>15,16</sup>, while the ET<sub>B</sub> receptor knockout model is characterized by significant CNS disturbances and proves fatal within 4 weeks of birth<sup>13,15</sup>. Ontological studies have demonstrated the integral function of ET<sub>B</sub> receptors within the developing CNS, promoting neuronal proliferation and migration as well as angiogenic growth factors<sup>14,16</sup>. ET<sub>B</sub> receptors play a crucial role not only in the developmental stage of the CNS,

---

<sup>1</sup>Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, 60515, USA. 2Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, 60515, USA. 3Present address: Pharmazz, Inc., Research and Development, Willowbrook, IL, USA. Correspondence and requests for materials should be addressed to A.G. (email: anil.gulati@pharmazz.com)
but their stimulation following CNS damage in adults has also been shown to enhance neurogenesis and angiogenesis, thereby promoting CNS repair and regeneration.27-19.

Previous studies from our laboratory have demonstrated that selective stimulation of ET<sub>B</sub> receptors by agonist, IRL-1620, could significantly improve neurological and motor functions, with concurrent decrease in infarct volume and oxidative stress damage following permanent middle cerebral artery occlusion (MCAO) in rats.20,21. IRL-1620 treatment post cerebral ischemia has been shown to protect neurons while enhancing angiogenesis, as noted by an increase in both neuronal nuclei and vascular endothelial growth factor (VEGF). Additionally, animals receiving IRL-1620 displayed increased numbers of proliferating cells and cells positively staining for nerve growth factor (NGF) in the infarcted brain.22. Recently, a clinical trial phase I was conducted and IRL-1620 was found to be safe and well tolerated in healthy human volunteers (CTRI/2016/11/007509).23. A randomized, double blind, controlled, multicenter phase II trial is in progress in patients with cerebral ischemic stroke (CTRI/2017/11/010654).

Our studies indicate the neuroprotective and neurorestorative roles of ET<sub>B</sub> receptor stimulation by IRL-1620 following cerebral ischemia. However, anti-apoptotic pathway involved in IRL-1620’s neuroprotective effects after ischemia remain to be identified. Neuronal apoptosis is a significant factor in neurological disorders associated with ischemia. Anti-apoptotic mechanisms in the rat cortical neurons have been shown to be positively affected by ET<sub>B</sub> receptor agonists.24,25. Increased neuronal apoptosis has been observed in areas containing progenitor cells of spotting-lethal (sl/sl) rats lacking functional ET<sub>B</sub> receptors.8,13.

In the present study, cerebral ischemia was induced in rats by permanent MCAO, and then they were treated with vehicle or IRL-1620 (5 µg/kg, i.v.) at 2, 4, and 6 h post-occlusion. We determined cerebral blood flow using laser Doppler flow meter before, 1 h and on day 7 post MCAO. Behavioral parameters and analysis of cell survival and apoptotic pathways markers e.g. Akt, pAkt, Bcl-2, Bad and Bax (cytotoxic and mitochondrial membrane-bound) were carried out in sham, IRL-1620 and vehicle-treated MCAO rats at 7 h, 24 h and day 7 post occlusion. We also assessed the DNA fragmentation (a hallmark of the end stage apoptosis) by TUNEL assay.

### Results

**IRL-1620 treatment alleviates neurological deficit in MCAO rats.** Seven hours, 24 h and day 7 after MCAO of the right side, paresis of the left hind limb was observed. No difference in the mean neurological score of vehicle and IRL-1620-treated animal was observed at 7 h post MCAO. At 24 h and Day 7 post MCAO, compared to sham-operated rats, the mean neurological score of vehicle-treated rats was significantly higher (P < 0.001), indicative of neurological impairment following induction of cerebral ischemia. In contrast, MCAO rats treated with IRL-1620 demonstrated significant improvement in neurological function when compared with the vehicle group (P < 0.001) (Table 1).

**IRL-1620 treatment improves motor function and coordination in MCAO rats.** While there was no difference in motor function or coordination in any of the animals prior to occlusion, significant impairment was noted 7 h, 24 h and day 7 after induction of cerebral ischemia. No significant difference was observed in functional parameters between vehicle and IRL-1620-treated animal at 7 h post MCAO (Table 1).

**Grip test.** Vehicle-treated rats demonstrated a significant decrease in muscle strength following MCAO compared to sham-operated rats (P < 0.001). In contrast, rats treated with IRL-1620 showed significant improvement (P < 0.001) when compared with vehicle-treated rats, with mean scores of 3.5 ± 0.2 vs. 0.5 ± 0.2, respectively 24 h post MCAO and 4.4 ± 0.3 vs. 1.5 ± 0.4, respectively day 7 post MCAO (Table 1).

**Foot fault.** A less than 10% foot fault error was observed prior to occlusion. After MCAO, a lack of motor coordination was found in vehicle-treated animals, with this group of animals having a significantly higher percentage

| Treatment Groups | Time points | Neurological deficit (6 point scale) | Grip test (6 point scale) | Foot fault error (%) | Rota rod duration (Sec) | Distance traveled (cm) |
|------------------|-------------|-------------------------------------|--------------------------|---------------------|------------------------|------------------------|
| Sham | Baseline | 0 ± 0 | 5 ± 0 | 2.8 ± 1.3 | 133.2 ± 7.3 | 3957.8 ± 464.9 |
| | 7 h post MCAO | 0 ± 0 | 4.2 ± 0.3 | 2.8 ± 0.3 | 143.2 ± 14.5 | 3446.6 ± 296.6 |
| | 24 h Post MCAO | 0 ± 0 | 4.8 ± 0.2 | 9.1 ± 0.4 | 183.1 ± 9.9 | 3758.2 ± 265.9 |
| | Day 7 post MCAO | 0 ± 0 | 3.6 ± 0.2 | 5.5 ± 1.5 | 142.8 ± 18.7 | 4160.8 ± 501.8 |
| MCAO + Vehicle | Baseline | 0 ± 0 | 4.2 ± 0.2 | 2.4 ± 1.5 | 134.8 ± 7.8 | 3901.8 ± 472.3 |
| | 7 h post MCAO | 2.5 ± 0.2* | 1.5 ± 0.7* | 58.5 ± 14.9* | 64.0 ± 8.0* | 543.6 ± 170.2* |
| | 24 h Post MCAO | 4.0 ± 0.3* | 0.5 ± 0.2* | 86.0 ± 4.0* | 43.0 ± 5.8* | 269.3 ± 129.6* |
| | Day 7 post MCAO | 2.3 ± 0.2* | 1.5 ± 0.4* | 44.3 ± 8.1* | 113.7 ± 19.6 | 2882.0 ± 249.6* |
| MCAO + IRL-1620 | Baseline | 0 ± 0 | 4.5 ± 0.2 | 2.2 ± 1.4 | 122.5 ± 12.0 | 4010.3 ± 312.3 |
| | 7 h post MCAO | 1.8 ± 0.4 | 2.1 ± 0.5* | 39.9 ± 5.8* | 112.0 ± 35.0 | 1275.6 ± 293.8* |
| | 24 h Post MCAO | 1.8 ± 0.2* | 3.5 ± 0.2* | 19.6 ± 3.8* | 125.1 ± 7.3* | 3562.6 ± 256.3* |
| | Day 7 post MCAO | 0.8 ± 0.1** | 4.4 ± 0.3* | 11.8 ± 4.4* | 163.4 ± 22.8* | 3782.7 ± 552.8** |

Table 1. Effect of ET<sub>B</sub> receptor agonist, IRL-1620, on neurological deficit and motor functions at baseline, 7 h and 24 h post MCAO in rats. Values are expressed as mean ± S.E.M. *P < 0.001 compared to sham. †P < 0.01 compared to MCAO + vehicle. ‡P < 0.05 compared to 7 h post MCAO + IRL-1620.
of foot fault errors compared to sham (P < 0.001). Treatment with IRL-1620, resulted in improved coordination, with a significantly lower percentage of error as compared with vehicle-treated rats (19.6 ± 3.8% vs. 86.0 ± 4.0% at 24 h; 11.8 ± 4.4% vs. 44.3 ± 8.1% at day 7; P < 0.01) (Table 1).

Rota rod. After occlusion, vehicle-treated MCAO rats demonstrated poor coordination by failing to remain on the rod when compared with sham-operated animals (P < 0.001). IRL-1620-treated occluded rats demonstrated significant improvement in motor coordination (125.1 ± 7.3 s and 163.4 ± 22.8 s at 24 h and day 7, respectively) compared with vehicle-treated rats (43.0 ± 5.8 s and 113.7 ± 19.6 s; P < 0.01) (Table 1).

Locomotor activity. Spontaneous motor activity was comparable in all groups prior to occlusion. Following MCAO, vehicle-treated rats were moving significantly (P < 0.001) less than the sham-operated. However, when IRL-1620 was administered, spontaneous activity was significantly (p < 0.01) increased (Table 1).

IRL-1620 increases phosphorylation of Akt transiently and decreases Bad expression. We observed a significant increase in the phosphorylation of Ser473 of Akt (pAkt) in right (occluded) hemisphere of IRL-1620 treated rats compared to the sham (P < 0.01) and vehicle-treated (P < 0.05) rats 7 h post MCAO; however, no significant difference in pAkt level was seen among the groups at 24 h post MCAO. Moreover, no significant change was noticed in total Akt expression among these groups at 7 h and 24 h post MCAO (Fig. 1A).

We also examined the expression of the pro-apoptotic protein, Bad at 7 h and 24 h post MCAO in these samples. At 7 h post MCAO, a significant decrease in total Bad expression was observed in the right (occluded) hemisphere of the IRL-1620-treated rats compared to the sham and vehicle-treated groups (P < 0.05) as well as compared to the contralateral hemisphere of the IRL-1620-treated rats (P < 0.05). However, no change in total Bad expression was observed at 24 h post MCAO. We also assessed the level of phospho-Bad (inactive form) at 7 h and 24 h post MCAO. There was no difference in the phosphorylation of the Ser136 residue of Bad (pBad) 7 h post MCAO; however, a decreased level of phospho-Bad (pBad) was observed in the occluded hemisphere of the vehicle-treated group compared to the sham and IRL-1620-treated rats (P < 0.05) 24 h post MCAO (Fig. 1B).

IRL-1620 upregulates anti-apoptotic Bcl-2 and downregulates pro-apoptotic Bax expression. In the right (occluded) hemisphere of the vehicle-treated rats, expression of Bcl-2 was decreased at 7 h, 24 h and day 7 post MCAO compared to sham (p < 0.001). On the other hand, in IRL-1620-treated rats Bcl-2 expression was increased in the occluded hemisphere compared to vehicle-treated rats (P < 0.001) at 7 h, 24 h and day 7 post MCAO. In comparison to sham at 7 h and 24 h post-surgery, the Bcl-2 expression in IRL-1620-treated animals was also significantly (P < 0.05) increased (Fig. 2A). As expected, pro-apoptotic Bax expression was upregulated in vehicle-treated animals in response to ischemia compared to sham; however, IRL-1620 treatment significantly attenuated the ischemia-induced increase in Bax expression (P < 0.001) at 7 h, 24 h and day 7 post MCAO (Fig. 2B).

The Bcl-2 family proteins are known as an important gatekeeper to the apoptotic response in the neuronal mitochondria-pathway. Following a death stimulus, cytosolic and monomeric Bax proteins change to homo-oligomeric form and translocate to the mitochondrial outer membrane and assist the flow of apoptotic
factors to the cytosol. Thus, integration of Bax into the mitochondrial membrane is a critical step of apoptosis from where the reversal of apoptosis is highly unlikely. Therefore, detection of mitochondrial membrane-bound Bax would be a highly relevant indicator of apoptosis than cytosolic alone. We used immunofluorescence technique to detect the co-localization of Bax and mitochondria in the rat brain tissues after staining with anti-Bax and mitotracker dye. We observed very low levels of Bax expression in sham but significantly higher expression in vehicle-treated animals at both 24 h (Fig. 3A,B) and day 7 post MCAO (Fig. 3D,E). Treatment with IRL-1620 decreased the Bax expression significantly compared to the vehicle group (Fig. 3), which confirm the results obtained from western blot (Fig. 2B). Interestingly, when we analyzed the microscopic images for co-localization of Bax and mitochondria, we observed a higher amount of Bax co-localization with mitotracker dye in the vehicle group compared to IRL-1620-treated animals at both 24 h (Fig. 3A,C) and day 7 post MCAO (Fig. 3D,F).

IRL-1620 treatment decreases DNA fragmentation. TUNEL assay was employed to study the effect of IRL-1620 on DNA fragmentation at 24 h and day 7 after MCAO. A significant amount of TUNEL-positive cells at 24 h and day 7 post MCAO were detected in the vehicle-treated group (87.9 ± 5.2 and 72.4 ± 4.3 per 750 µm², respectively) as compared with the sham-operated group. After treatment with IRL-1620, the level of DNA fragmentation in the ischemic hemisphere was significantly decreased at 24 h and day 7 (17.2 ± 1.6 and 15.6 ± 1.3 per 750 µm², respectively, P < 0.001) when compared to the vehicle group (Fig. 4).

IRL-1620 treatment improves cerebral blood flow (CBF) and decreases infarct volume in MCAO rats. We assessed the CBF 15 min prior to MCAO (baseline), 1 h and day 7 post MCAO. There was 40–45% reduction in CBF in the occluded hemisphere compared to baseline at 1 h post MCAO. CBF in the vehicle-treated group remained unchanged (~41.9 ± 5.0%, below baseline), whereas CBF significantly (p < 0.001) improved in IRL-1620-treated animals (~12.0 ± 12.9%, above baseline) after day 7 post MCAO (Fig. 5).

There was no significant difference in the infarct volume of vehicle and IRL-1620-treated animal at 7 h post MCAO (157.1 ± 15.9 and 151.3 ± 20.7 mm³, respectively). Cerebral ischemia post MCAO resulted in an infarct volume of 181.6 ± 16.0 and 153.4 ± 15.5 mm³ in rats treated with vehicle at 24 h and day 7, respectively. IRL-1620 treatment significantly decreased the infarct volume at 24 h and day 7 post MCAO (33.9 ± 5.1 and 41.4 ± 13.4 mm³, respectively; P < 0.001) compared to vehicle treated animals (Fig. 6).

Discussion

We have demonstrated that selective stimulation of the ET₂ receptors enhances neurovascular repair with significant reductions in neurological deficit, infarct volume and oxidative stress in rat models of cerebral ischemia. We also observed higher cell proliferation (BrdU⁺ cells) in IRL-1620-treated rat brains compared to control, however its role in protection of cells against apoptotic damage during stroke remained elusive. Since the
Figure 3. Bax translocation to mitochondria in cerebral ischemia-induced apoptosis. Bax was immuno-stained with anti-Bax and the mitochondria were stained with MitoTracker (green). The merged image indicates colocalization of Bax on mitochondria. Values are expressed as mean ± S.E.M. *P < 0.01 compared to sham, @P < 0.001 compared to MCAO + vehicle.

Figure 4. TUNEL positive cells per 750 µm² in the ischemic region were detected by TUNEL staining 24 h and day 7 after MCAO. Values are expressed as mean ± S.E.M. *p < 0.0001 compared to sham; @p < 0.001 compared to vehicle.
inhibition of apoptotic cell death has been reported as an important event in the neuroprotection\textsuperscript{29,30}, we conducted this study to determine whether ET\textsubscript{B} receptor stimulation also affects the apoptotic pathways following ischemia. We used a well-established method of permanent middle cerebral artery occlusion (MCAO) in rats to induce ischemia in the brain. We have been regularly using this procedure in our lab for more than 10 years and produces highly consistent results confirmed by measuring CBF using laser Doppler flow meter. It involves occlusion of MCA, which is most often affected in human ischemic stroke and accounts for \(\sim70\%\) of infarcts\textsuperscript{31}. Thus, the MCAO technique is the closest to human ischemic stroke with affecting similar regions of the brain in animal models. Other advantages of the MCAO model include large infarct volume and high reproducibility. It has been demonstrated that the MCAO technique is the most preferred technique for reproducing ischemic stroke, as it results in neural cell death, inflammation, damage to the blood brain barrier as well as producing dependable results in behavior tests. Therefore, among the occlusive models for stroke the MCAO technique is the model of choice and has been used in more than 40\% of all the experiments (\(\sim2600\)) on neuroprotection after ischemic stroke\textsuperscript{32}. After successful MCAO, the rats were randomly selected for injection of either IRL-1620 (5 \(\mu\)g/kg) or saline (vehicle) at 2, 4 and 6 h post occlusion. The dose of IRL-1620 was based on our previous studies\textsuperscript{20–22} and Phase I safety and tolerability studies, where the Minimum Intolerable Dose (MID) for IRL-1620 was established as 0.9 \(\mu\)g/kg and the Maximum Tolerated Dose (MTD) was 0.6 \(\mu\)g/kg (CTRI/2016/11/007509)\textsuperscript{23}. According to dose by factor method the dose of 0.6 \(\mu\)g/kg (MTD) in human is approximately equivalent to 5 \(\mu\)g/kg in rats\textsuperscript{33}. The half-life of IRL-1620 ranges from 4.38 min to 8.29 min\textsuperscript{34}. The observed half-life of IRL-1620 is short; however, a longer duration of action is possible similar to the ET-1 signaling, where ET-1 and its receptors get internalized within 10 min and continues to signal for days\textsuperscript{35–37}. We sacrificed rats at 7 h, 24 h and day 7 post MCAO for analysis of different parameters. The analyses of cerebral blood flow (noninvasive) at 1 h and infarct size measurement at 7 h post occlusion showed similar blood flow reduction and infarct size in both groups, which confirmed the consistency of the effect of occlusion across the
groups. However, significantly improved blood flow in IRL-1620 compared to vehicle was observed at day 7 and the infarct size was reduced significantly in IRL-1620 treated rats compared to vehicle at 24 h and day 7, which suggested improved neuroprotection in IRL-1620 treated animals. In line with these results, we also observed improvements in neurological and motor function in IRL-1620 treated animals compared to vehicle. These results revalidated our previous findings related to the effects of IRL-1620 in the MCAO rat model and also warranted further studies to investigate the anti-apoptotic mechanism of action of IRL-1620 in the infarcted rat brains.

It has been observed that ET-1 binding to endothelial cell ET$_B$ receptors in vitro leads to increased Akt phosphorylation at Ser473, endothelial nitric oxide synthase (eNOS) phosphorylation at Ser1179, and NO synthesis. Also, overexpression of a dominant negative G-protein-coupled receptor kinase construct that sequesters βγ sub-units has been shown to inhibit Akt phosphorylation and NO synthesis. While Akt phosphorylation is generally believed to occur through tyrosine kinases, these data demonstrate that the G-protein-coupled ET$_B$ receptors can signal the PI3K/Akt pathway. Activation of the PI3K/Akt pathway has been widely reported to participate in the protection against cerebral ischemia and lower levels of Ser473 phosphorylation were correlated with worsening damage associated with ischemia.

In this study, we observed transiently elevated pAkt (Ser473) levels in IRL-1620-treated MCAO animals at the early stage of ischemia, suggesting its role in mediating the neuroprotective effect of ETB receptor stimulation. It has been reported that phosphorylation of Akt at Ser473 and Thr308 leads to subsequent phosphorylation of Bad and affects apoptosis. Therefore, we assessed the expression of Bad and its phosphorylation after IRL-1620 treatment following ischemia. The total Bad expression level was significantly decreased in IRL-1620-treated animals in the occluded hemisphere compared to sham and vehicle-treated groups 7 h post MCAO, while we observed similar expression of Bad among all the groups at 24 h. We analyzed phospho-Bad in these groups and found no change at 7 h post MCAO among the groups; however, decreased phosphorylation of Bad in vehicle-treated animals at 24 h post MCAO was observed. Furthermore, treatment with IRL-1620 increased the phosphorylation of Bad compared to vehicle-treated animals and reached similar levels to sham at 24 h post MCAO. It is possible that transiently increased pAkt levels in the IRL-1620 group will still play a role in modulating Bad activity and maintaining pBad levels similar to sham levels 24 h post MCAO.

Other major regulatory proteins involved in regulating the early stages of apoptosis include Bcl-2 and Bax, which are downstream targets of Akt. Previous studies have demonstrated that various neuroprotective treatments may have the capacity to reduce the impact of stroke via increased expression levels of either Bcl-2 or Bcl-xL. We observed decreased Bcl-2 expression and increased Bax expression in vehicle-treated MCAO animals. Interestingly, treatment with IRL-1620 upregulated Bcl-2 expression while downregulated Bax expression following MCAO. Bax is a pro-apoptotic Bcl-2 family protein and plays an important role in the mitochondria-mediated apoptosis pathway. It is a cytosolic protein and normally remains in the cytosol; however, during apoptosis its conformational change causes homo-oligomerization and integration into the outer mitochondrial membrane (OMM). The insertion of Bax into the OMM leads to pore formation and release of apoptotic factors (e.g. apoptosis-inducing factor, endonuclease G, cytochrome c etc.) into the cytosol. Release of these factors into cytosol may lead to caspase-independent (AIF, endonuclease G) or caspase-dependent (cytochrome C) DNA fragmentation and ultimately cell death.
integration of Bax into mitochondrial membrane is a critical step of apoptosis from where the reversal of apoptosis is highly unlikely. Therefore, detection of mitochondrial membrane bound Bax would be a better indicator of apoptosis than cytosolic Bax. We used immunofluorescence technique to detect the co-localization of Bax and mitochondria. We observed significantly higher expression of Bax in vehicle-treated animals at 24h and day 7 post MCAO compared to sham. Treatment with IRL-1620 significantly decreased Bax expression compared to vehicle. Interestingly, when we analyzed the microscopic images for co-localization of Bax and mitochondria, we observed higher amounts of Bax co-localization with mitochondrial dye in vehicle compared to IRL-1620-treated animals. These observations indicate that IRL-1620 could modulate apoptotic signaling pathway and thus interfere with the docking of Bax to the mitochondrial membrane. Moreover, the results of the TUNEL assay showed a significant decrease in DNA end labeling (an indicator of DNA fragmentation) in IRL-1620 compared to vehicle-treated animals.

The pathophysiology of cerebral ischemia involves multiple complex pathways including vascular remodeling (angiogenesis/vasculogenesis), which plays an important role in repair and regeneration. Angiogenic substances in ischemic conditions have been shown to increase CBF as well as inhibit apoptosis. Moreover, our previous study has demonstrated that ETβ receptor stimulation increases the expression of a potent angiogenic factor, VEGF, in the ischemic rat model. Therefore, in the present study we have examined the blood flow at 1 h and day 7 post MCAO, using laser Doppler flow meter. A significant decrease in CBF was noted in the ipsilateral (occluded) hemisphere following MCAO as expected; however, a decrease in CBF in the contralateral hemisphere was also observed. A pressure gradient often occurs between neighboring arterial fields when there is a significant change in perfusion, particularly with the occlusion of a large vessel. This gradient subsequently results in alterations of collateral blood flow rate and direction, which may explain the observed decrease in CBF in the non-occluded hemisphere. As we occluded the MCAO permanently, the filament remains in the artery and might cause a rapid drop in intraluminal pressure and vascular resistance, leading to a collateral circulation fail during initial hours, thereby reducing CBF in the contralateral hemisphere as well as the ipsilateral. We observed a significant increase in CBF in IRL-1620-treated animals at day 7 post MCAO. It is possible that IRL-1620 could be limiting the injury due to ischemia by improving the CBF and by inhibiting the apoptotic pathway.

Taken together, these results indicate that IRL-1620 improves CBF, increases the level of pAkt, which attenuates its downstream target Bad, upregulates Bcl-2 expression and interferes with Bax translocation to the OMM, thereby reducing ischemic neural cell death as observed via TUNEL assay and reducing infarct size (Fig. 7). Based on our previous as well as the present studies, we suggest that stimulation of ETβ receptors via IRL-1620 may serve as a multimodal therapeutic agent for the treatment of stroke, providing neuroprotection from apoptosis and oxidative stress as well as enhancing endogenous neurovascular repair mechanisms. Results of these studies support the clinical development of IRL-1620 for patients with cerebral ischemia.

Methods

Animals. Male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing 350–375 g were allowed to acclimate for at least 4 days before use in a room with controlled temperature (23 ± 1 °C), humidity (50 ± 10%), and light (6:00 A.M. to 6:00 P.M.). Food and water were available continuously. Animal care and use of anesthetics and surgical procedures were approved by the IACUC of Midwestern University and were performed in accordance with guidelines and regulations of the U.S. National Institutes of Health. Rats were randomly divided into three groups (Group 1: Sham, Group 2: MCAO + Vehicle, Group 3: MCAO + IRL-1620) with an n = 6/group for each assessment – infarct volume, protein estimation and TUNEL assay – at 7 h, 24 h, and day 7.

Drugs. Ketamine (Henry Schein Animal Health, Dublin, OH, USA) was administered at a dose of 100 mg/kg, intraperitoneally (i.p.), and xylazine (Lloyd Laboratories, Shenandoah, IA, USA) was administered at a dose of 10 mg/kg, i.p. IRL-1620 [N-Succinyl-[Glu9, Ala11,15] endothelin 1] (Bachem Americas, Inc., Torrance, CA 90505) was dissolved in isotonic saline and administered at a dose of 5 µg/kg, intravenously (i.v.) via tail vein at 2, 4 and 6 h post MCAO. The dose of IRL-1620 was based on our previous studies20–22 and Phase I safety and tolerability studies.

Middle cerebral artery occlusion to induce focal cerebral ischemia. Induction of focal cerebral ischemia via MCAO was performed according to the method of Koizumi, et al. with modification of access route. Rats were anesthetized with ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). A rectal core temperature of 37 ± 1 °C was maintained throughout the operation and recovery from surgery using the thermo-controlled base of the operating table, measured with a Cole Palmer Animal Monitoring Thermometer with colonic probe (Vernon Hills, IL, USA). With the animal in a secure supine position, a midline incision was made and the right common carotid artery, external carotid artery, and internal carotid artery were exposed. A 4.0 monofilament nylon thread (CP Medical, Portland, OR, USA) was advanced from the external carotid artery into the lumen of the internal carotid artery until a resistance was felt (~20 mm), indicating occlusion of the middle cerebral artery. The nylon filament was allowed to remain in place to create a permanent model of focal cerebral ischemia. The common carotid artery and external carotid artery were exposed in sham animals and the incision was sutured without touching the internal carotid artery. Animals were monitored until fully recovered from anesthesia on the day of surgery, and then observed for well-being 2x/day until the end of the experiment. Mortality for the day 7 study included 2 animals in the vehicle-treated group, which were then removed from the study. These animals were then repeated in order to meet the number of animals required for statistical power at the day 7 endpoint. No mortality was observed in the 7 h or 24 h studies.
Neurological evaluation. Animals were subjected to a neurological evaluation prior to occlusion, and at 7 h, 24 h, and day 7 post MCAO. A 6 point scale to assess neurological deficit was used, with 0 indicating no deficit and 5 representing death, as described in previous studies.

Motor performance tests. Four assessments were used to determine motor activity and coordination following MCAO. Animals were subject to blinded assessments prior to occlusion, and 7 h, 24 h, and day 7 post MCAO using a grip test, foot fault test, rota rod and spontaneous locomotor activity.

Grip test. The grip test consisted of a string 50 cm in length, pulled taut between two vertical supports and elevated 40 cm above a flat surface. The animal was placed on the string midway between the supports and evaluated according to a 6 point scale.

Foot fault test. Animals were placed on an elevated grid floor with a mesh size of 30 mm for one minute to acclimate. They were then observed for one minute and evaluated for foot fault errors as described earlier.

Rota rod. Prior to MCAO, animals were acclimated to the rotating spindle of the rota rod apparatus (Rota-Rod 47700, Ugo Basile, Italy) as described earlier. Animals were then placed on the rotating spindle for acceleration trial and the time at which they fell off was recorded in seconds.

Spontaneous locomotor activity. Spontaneous locomotor activity was assessed using an animal activity meter (Opto-Varimex-4 Auto-Track System, Columbus Instruments, Columbus, OH). Each animal was observed for a period of 10 min in a square enclosed area equipped with infrared photocells along the X, Y, and Z axes to quantitatively measure spontaneous horizontal and vertical motion.

Cerebral blood flow. Cerebral blood flow (CBF) was monitored using Laser Speckle Contrast Analysis (LASCA) via the PeriCam PSI High Resolution System (Perimed, Sweden). The rats were anesthetized and a
paramedian skin incision was performed. The subcutaneous tissue and cranial fascia were dissected to reach the skull bone. The rats were then positioned precisely 10 cm below the laser with a 1.1 cm² field centered over the midline. CBF was monitored at a frame rate of 25 images/sec for 15 minutes before, and at 1 h and day 7 post MCAO. Baseline CBF readings taken 15 min prior to occlusion were compared with CBF readings taken at 1 h and day 7 post MCAO. Complete occlusion of the MCA was considered to have occurred when the infarcted hemisphere demonstrated a >40% decrease in CBF at 1 h post MCAO as compared to baseline.

Assessment of cerebral infarct volume. Brains were removed to determine infarct volume at 7 h, 24 h and day 7 post MCAO. Animals were anesthetized with ketamine and xylazine and euthanized by decapitation. The brains were quickly removed and chilled in saline at 4 °C for 5 min. They were then cut into 2 mm thick coronal slices using a Brain Matrix (Harvard Apparatus, Holliston, MA). Sections were incubated in 2% 2,3,5-triphenyltetrazolium chloride (TTC, Sigma, St. Louis, MO) dissolved in saline for 15 min at 37 °C[67]. Infarct volumes were calculated by sampling each side of the coronal sections with a digital camera (Nikon, Melville, NY). The infarct area, outlined in white, was measured by image analysis software (Adobe Photoshop CS6). Infarct size is expressed as infarction volume in mm³ as the sum of infarct areas in each slice, corrected for edema[21].

Estimation of apoptotic markers. At 7 h, 24 h, and day 7 post MCAO, animals were euthanized by decapitation, and the brains were removed for western blot analysis. Brain tissues were washed in chilled saline and homogenized in RIPA buffer (20 mM Tris-HCl pH 7.5, 120 mM NaCl, 1.0% Triton X100, 0.1% SDS, 1% sodium deoxycholate, 10% glycerol, 1 mM EDTA and 1X protease inhibitor, Roche). Proteins were isolated in solubilized form and concentration was determined using Folin–Ciocalteu’s Reagent[48]. Solubilized protein (60 µg) was denatured in Laemmli sample buffer (Bio–Rad, Hercules, CA), resolved in 10% SDS–PAGE and transferred on nitrocellulose membrane (Sigma–Aldrich, St. Louis, MO, USA). The membrane was then blocked with super–block solution for 1 h at room temperature. The membranes were incubated overnight with rabbit polyclonal anti-Akt, pAkt, Bad, pBad, Bax and Bcl-2 antibodies (1:1000) (Cell Signaling Technology, Danvers, MA, USA) at 4 °C overnight, followed by incubation with goat anti-rabbit IgG, horseradish peroxidase-conjugated (HRP) secondary antibody (1:2000) (Santa Cruz Biotech., Santa Cruz, CA, USA) for 2 h at room temperature. β-actin (1:10,000; Sigma–Aldrich, St. Louis, MO, USA) was used as a loading control. The labeled proteins were visualized with SuperSignal WestPico Chemiluminescent Substrate (Thermo Fisher Scientific, Bartlett, IL) using the Kodak Gel Logic 1500 Imaging System (CarestreamHealth Inc., New Haven, CT). Protein expression was analyzed using ImageJ (NIH) software[45].

Immunofluorescence. To confirm western blot data and examine the sub-cellular localization of Bax in relation to mitochondria, we used immunofluorescence technique to detect the co-localization of Bax and mitochondria in the rat brain tissue after staining with anti-Bax and mitotracker dye (Nonyl Acridine Orange, Thermo Fisher Scientific, Waltham, MA). We selected this dye because of its property to enter into mitochondria independently of their membrane potential. Therefore, it is suitable to use in live cells as well as in fixed tissues. At 24 h and day 7 following MCAO, animals underwent transcardial perfusion to fix the brains. The brains were post-fixed in 50 ml of 4% PFA in NaPO4 buffer solution for 2 h, and then placed in 20% sucrose/4% PFA, pH 7.4, 50 ml/brain at 4 °C for 48 h. The brains were then sliced into 10 µm thick slices for immunofluorescent analyses at −20 °C using a cryostat (Microm cryostat HM 505E; Walldorf, Germany). The brain sections were washed with 1X HBSS twice and incubated with 5 µM Mitotracker dye (prepared in 1X HBSS) for 30 minutes at room temperature. After washing three times with 1X PBS, permeabilization was performed with 1% Triton-x100 in PBS for 15 minutes at room temperature. Blocking was performed with 5% BSA in 1X PBS for 1 h at room temperature. The brain sections were incubated with anti-Bax antibody (1:200 diluted in 1X PBS) at 4 °C overnight. Sections were washed twice in 1X PBS and incubated with Alexa Fluor 555-conjugated donkey anti-rabbit secondary antibody (1:200; Abcam, Cambridge, MA) for 1 h at room temperature. The sections were then washed with 1X HBSS, incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG, and then mounted with vector mount medium (Vector Laboratories, Burlingame, CA). Fluorescence was detected using an inverted fluorescent microscope (Nikon Eclipse TiE, Melville, NY). All images for analysis were taken with the same exposure with a multi-channel ND acquisition using NIS Elements BR imaging software (Nikon Instruments, Inc., Melville, NY). Analyses was performed using NIS-Elements 3.01 imaging software from Nikon Instruments, Inc. (Melville, NY).

Terminal deoxynucleotidyl transfer-mediated dUTP nick end labeling (TUNEL) assay. At 24 h and day 7 following MCAO, animals underwent transcardial perfusion to fix the brains. The brains were post-fixed in 50 ml of 4% PFA in NaPO4 buffer solution for 2 h, and then placed in 20% sucrose/4% PFA, pH 7.4, 50 ml/brain at 4 °C for 48 h. The brains were then sliced into 10 µm thick slices for immunofluorescent analyses at −20 °C using a cryostat (Microm cryostat HM 505E; Walldorf, Germany). Coronal cryostat sections were processed according to the manufacturer’s instructions for TUNEL assay using Click-it TUNEL Alexa Fluor Imaging Assay kit (Molecular Probes, Invitrogen, NY, U.S.A.). Cells exhibiting DNA fragmentation (TUNEL positive) were counted in the tissues using inverted fluorescent microscope (Nikon Eclipse TiE, Melville, NY) in a blinded fashion[54,69].

Statistical analysis. A Power Analysis was conducted using GraphPad Instat-3.1 with a beta of 0.05. The sample size in each group was N = 6 based upon expected change determined from results published in literature using similar procedures. Data are presented as mean ± S.E.M. Two-way analysis of variance (ANOVA) was used for intergroup comparison for behavioral data. One-way ANOVA followed by Bonferroni’s post hoc comparison test was used for intergroup comparison to evaluate infarct volume and apoptotic markers.
A P value of less than 0.05 was considered to be significant. The statistical analysis was processed with GraphPad Prism 6.00 (GraphPad, San Diego, CA, USA).

References
1. Benjamin, E. J. et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation 135, e1–e603, https://doi.org/10.1161/CIR.0000000000000485 (2017).
2. Baynash, A. G. et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 79, 1277–1285 (1994).
3. Choi, D. W. Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends in neuropsychology 18, 58–60 (1995).
4. Elkind, F. J., Malik, K. U. & Shea, T. B. Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. The Journal of biological chemistry 274, 30322–30327 (1999).
5. Lahav, R. et al. Endothelin 3 selectively promotes survival and proliferation of neural crest-derived glial and melanocytic precursors in vitro. Proceedings of the National Academy of Sciences of the United States of America 95, 14214–14219 (1998).
6. Arai, H., Hori, S., Aramori, I., Oikubo, H. & Nakashima, S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348, 730–732, https://doi.org/10.1038/348730a0 (1990).
7. Yanagisawa, M. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411–415, https://doi.org/10.1038/332411a0 (1988).
8. Castaneda, M. M., Cubilla, M. A., Lopez-Vicchi, M. M. & Suburo, A. M. Endothelinergic cells in the subependymal region of mice. Brain research 1331, 20–30, https://doi.org/10.1016/braintre.2010.01.056 (2010).
9. Ehrenreich, H. et al. Endothelin B receptor deficiency is associated with an increased rate of neuronal apoptosis in the dentate gyrus. Neuroscience 95, 993–1001 (2000).
10. Gulati, A., Kumar, A., Morrison, S. & Shahani, B. T. Effect of centrally administered endothelin agonists on systemic and regional blood circulation in the rat: role of sympathetic nervous system. Neuropeptides 31, 301–309 (1997).
11. Sharifi, A. M. & Schiffrin, E. L. Apoptosis in aorta of deoxycorticosterone acetate-salt hypertensive rats: effect of endothelin receptor antagonism. Journal of hypertension 15, 1441–1448 (1997).
12. Shichiri, M., Kato, H., Marumo, F. & Hirata, Y. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 30, 1199–1203 (1997).
13. Rickers, C. C. et al. Endothelin B receptor deficient transgenic rescue rats: a rescue phenomenon in the brain. Neuroscience 124, 719–723, https://doi.org/10.1016/j.neuroscience.2003.10.023 (2004).
14. Vidovic, M. et al. Deficiency in endothelin receptor B reduces proliferation of neuronal progenitors and increases apoptosis in postnatal rat cerebellum. Cellular and molecular neurobiology 28, 1129–1138, https://doi.org/10.1007/s10751-008-9292-z (2008).
15. Dembowski, C. et al. Phenotype, intestinal morphology, and survival of homozygous and heterozygous endothelin B receptor–deficient (spotted lethal) rats. Journal of pediatric surgery 35, 480–488 (2000).
16. Leonard, M. G., Prazad, P., Puppala, B. & Gulati, A. Selective Endothelin-B Receptor Stimulation Increases Vascular Endothelial Growth Factor in the Rat Brain during Postnatal Development. Drug research 65, 607–613, https://doi.org/10.1055/s-0034-1396888 (2015).
17. Brialy, S., Nguyen, C., Leonard, M. & Gulati, A. Stimulation of endothelin B receptors by IRL-1620 decreases the progression of Alzheimer’s disease. Neuroscience 301, 1–11, https://doi.org/10.1016/j.neuroscience.2015.05.044 (2015).
18. Gulati, A. Understanding neurogenesis in the adult human brain. Indian journal of pharmacology 47, 583–584, https://doi.org/10.4103/0019-5413.99359 (2015).
19. Gulati, A. Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia. Current neuropharmacology 14, 619–626 (2016).
20. Leonard, M. G., Brialy, S. & Gulati, A. Endothelin B receptor agonist, IRL-1620, reduces neurological damage following permanent middle cerebral artery occlusion in rats. Brain research 1420, 48–58, https://doi.org/10.1016/j.brainres.2011.08.075 (2011).
21. Leonard, M. G., Brialy, S. & Gulati, A. Endothelin B receptor agonist, IRL-1620, provides long-term neuroprotection in cerebral ischemia in rats. Brain research 1464, 14–23, https://doi.org/10.1016/j.brainres.2012.05.005 (2012).
22. Leonard, M. G. & Gulati, A. Endothelin B receptor agonist, IRL-1620, enhances angiogenesis and neurogenesis following cerebral ischemia in rats. Brain research 1528, 28–41, https://doi.org/10.1016/j.brainres.2013.07.002 (2013).
23. Gulati, A., Hornick, M. G., Brialy, S. & Lavhale, M. S. A novel neuroregenerative approach using ET(B) receptor agonist, IRL-1620, to treat CNS disorders. Physiological research 67, S95–S113 (2018).
24. Yamagi, T. et al. Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. Brain research 948, 72–81 (2002).
25. Yamagi, T. et al. Effects of an endothelin B receptor agonist on secretory phospholipase A2-IIA-induced apoptosis in cortical neurons. Neuropharmacology 48, 291–300, https://doi.org/10.1016/j.neuropharm.2004.09.011 (2005).
26. Brinkmann, K. & Kashkar, H. Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell death & disease 5, e1098, https://doi.org/10.1038/cddis.2014.61 (2014).
27. O’Neill, K. L., Huang, K., Zhang, J., Chen, Y. & Luo, X. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes & development 30, 973–988, https://doi.org/10.1101/gad.276725.115 (2016).
28. Wei, M. C. et al. Preapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730, https://doi.org/10.1126/science.1095108 (2001).
29. Gu, N. et al. Anti-apoptotic and angiogenic effects of integrin-1 in rat cerebral ischemia. Brain research bulletin 130, 27–35, https://doi.org/10.1016/j.brainresbull.2016.12.006 (2017).
30. Kajimoto, M. et al. Selective cerebral perfusion prevents abnormalities in glutamate cycling and neuronal apoptosis in a model of infant deep hypothermic circulatory arrest and reperfusion. Journal of cerebral blood flow and metabolism 36, 1992–2004, https://doi.org/10.1038/s41598-019-46203-x (2016).
31. Fluri, F., Schuhmann, M. K. & Kleinschnitz, C. Animal models of ischemic stroke and their application in clinical research. Drug design, development and therapy 9, 3445–3454, https://doi.org/10.2147/DDDT.S66071 (2015).
32. Sommer, C. J. Ischemic stroke: experimental models and reality. Acta neuropathologica 133, 245–261, https://doi.org/10.1007/s00401-017-1667-0 (2017).
33. Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. Journal of basic and clinical pharmacy 7, 27–31, https://doi.org/10.4107/jbcp.017605.177703 (2016).
34. Reddy, G., Tolcher, A., Gulati, A., Chawla, S. & Allen L. F. Pharmacokinetics of SPI-1620 in a Phase I, open label, ascending dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the endothelin B receptor agonist, SPI-1620, in recurrent or progressive carcinoma. Life Sciences 25 (2013).
35. Archer, C. R., Robinson, E. L., Drawnel, F. M. & Roderick, H. L. Endothelin-1 promotes hypertrophic remodelling of cardiac myocytes by activating sustained signalling and transcription downstream of endothelin type A receptors. Cellular signalling 36, 240–254, https://doi.org/10.1016/j.cellsig.2017.04.010 (2017).
36. Bremnes, T. et al. Regulation and intracellular trafficking pathways of the endothelin receptors. The Journal of biological chemistry 275, 17596–17604, https://doi.org/10.1074/jbc.M001412200 (2000).
37. Chun, M., Lin, H. Y., Henis, Y. I. & Lodish, H. F. Endothelin-induced endocytosis of cell surface ETA receptors. Endothelin remains intact and bound to the ETA receptor. *The Journal of biological chemistry* **270**, 10855–10860 (1995).

38. Liu, S., Premont, R. T., Kontos, C. D., Huang, J. & Rockey, D. C. Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt. *The Journal of biological chemistry* **278**, 49929–49935, https://doi.org/10.1074/jbc.M306930200 (2003).

39. Liu, S., Premont, R. T. & Rockey, D. C. Endothelial nitric-oxide synthase (eNOS) is activated through G-protein-coupled receptor kinase-interacting protein 1 (GIT1) tyrosine phosphorylation and Src protein. *The Journal of biological chemistry* **289**, 18163–18174, https://doi.org/10.1038/jpc.2013.521203 (2014).

40. Song, G., Ouyang, G. & Bao, S. The activation of Akt/PKB signaling pathway and cell survival. *Journal of cellular and molecular medicine* **9**, 59–71 (2005).

41. Crowder, R. J. & Freeman, R. S. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. *The journal of neuroscience* **18**, 2933–2943 (1998).

42. Kilic, E. et al. The phosphatidylinositol 3-kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. *FASEB journal* **20**, 1185–1187, https://doi.org/10.1096/fj.05-4829ufe (2006).

43. Gabryel, B., Pudelko, A. & Malecki, A. Erk1/2 and Akt kinases are involved in the protective effect of aniracetam in astrocytes subjected to simulated ischemia in vitro. *European journal of pharmacology* **494**, 111–120, https://doi.org/10.1016/j.ejphar.2004.04.042 (2004).

44. Wang, S. J. et al. Potentiation of Akt and suppression of caspase-9 activations by electroacupuncture after transient middle cerebral artery occlusion in rats. *Neuroscience letters* **331**, 115–118 (2002).

45. Kilic, E., Kilic, U., Reiter, R. J., Bassetti, C. L. & Hermann, D. M. Tissue-plasminogen activator-induced ischemic brain injury is reversed by melatonin: role of inOSNs and Akt. *Journal of pineal research* **39**, 151–155, https://doi.org/10.1111/j.1600-079x.2005.00228.x (2005).

46. Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell* **91**, 231–241 (1997).

47. Broughton, B. R., Reuten, D. C. & Sobey, C. G. Apoptotic mechanisms after cerebral ischemia. *Stroke: a Journal of cerebral circulation* **40**, e331–339, https://doi.org/10.1161/STROKEAHA.108.533162 (2009).

48. Martinou, J. C. et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. *Neuron* **13**, 1017–1030 (1994).

49. Hata, R., Gillardon, F., Michaelidis, T. M. & Hossmann, K. A. Targeted disruption of the bcl-2 gene in mice exacerbates focal ischemic brain injury. *Metabolic brain disease* **14**, 117–124 (1999).

50. dual, B. D., Shaw, P. J., Wilson, M. E., Merchenthaler, I. & Wise, P. M. Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors. *Journal of neurochemistry* **19**, 6385–6393 (1999).

51. Kilic, E., Dietz, G. P., Hermann, D. M. & Bahr, M. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. *Annals of neurology* **52**, 617–622, https://doi.org/10.1002/ana.10356 (2002).

52. Small, S. S., Hsu, Y. T., Sanders, K. M., Russell, J. T. & Youle, R. J. Bax translocation to mitochondria subsequent to a rapid loss of mitochondrial membrane potential. *Cell death and differentiation* **8**, 909–920, https://doi.org/10.1038/sj.cdd.4400889 (2001).

53. Tikhomirov, O. & Carpenter, G. B. Axon activation and translocation to mitochondria mediate EGF-induced programmed cell death. *The Journal of cell science* **189**, 2060–2065; discussion 2066 (1997).

54. Liu, S., Premont, R. T., Kontos, C. D. & Rockey, D. C. Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt. *FASEB Journal* **11**, 2050–2055, https://doi.org/10.1242/ije.02676 (2005).

55. Namura, S., Nagata, I., Takami, S., Masayasu, H. & Kikuchi, H. Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice. *Stroke: a Journal of cerebral circulation* **32**, 1906–1911 (2001).

56. Penninger, J. M. & Kroemer, G. Mitochondria, AIF and caspases–rivaling for cell death execution. *Nature cell biology* **5**, 97–99, https://doi.org/10.1038/nclb0203-97 (2003).

57. Romero, J. R. et al. Cerebral collateral circulation in carotid artery disease. *Current cardiology reviews* **5**, 279–288, https://doi.org/10.2174/157340309793178857 (2009).

58. Symon, L., Ishikawa, S. & Meyer, J. C. Cerebral arterial pressure changes and development of leptomeningal collateral circulation. *Neurology* **13**, 237–250 (1963).

59. Cuccione, E., Padovano, G., Versace, A., Ferrarese, C. & Beretta, S. Cerebral collateral circulation in experimental ischemic stroke. *Experimental & translational stroke medicine* **8**, 2, https://doi.org/10.1186/s13231-016-0015-0 (2016).

60. Koizumi, J., Yoshida, Y., Nakazawa, T. & Oomena, G. Experimental studies of ischemic brain edema. I. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. *Japanese journal of stroke* **8**, 1–8 (1986).

61. Longa, E. Z., Weinstein, P. R., Carlson, S. & Cummins, R. Reversible middle cerebral artery occlusion without craniectomy in rats. *Stroke; a journal of cerebral circulation* **18**, 265–275 (1987).

62. Tatlisumak, T. et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. *Journal of pineal research* **39**(6), 59–71 (2005).

63. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. *FASEB Journal* **20**, 1185–1187, https://doi.org/10.1096/fj.05-4829ufe (2006).

64. Gabryel, B., Pudelko, A. & Malecki, A. Erk1/2 and Akt kinases are involved in the protective effect of aniracetam in astrocytes subjected to simulated ischemia in vitro. *European journal of pharmacology* **494**, 111–120, https://doi.org/10.1016/j.ejphar.2004.04.042 (2004).

65. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with the Folin phenol reagent. *The Journal of biological chemistry* **193**, 265–275 (1951).

66. Huse, B., Sopart, A. & Isenberg, G. Cyclic mechanical stretch-induced apoptosis in myocytes from young rats but necrosis in myocytes from old rats. *American journal of physiology. Heart and circulatory physiology* **285**, H1521–1527, https://doi.org/10.1152/ajpheart.00890.2002 (2003).

67. Yu, Y. S. et al. Apoptosis in granulosa cells during follicular atresia: relationship with steroids and insulin-like growth factors. *Cell research* **14**, 341–346, https://doi.org/10.1038/sj.cr.7290234 (2004).

Acknowledgements
The authors would like to acknowledge the funding provided by Midwestern University.
Author Contributions
Conceptualization: A.G., S.B., A.K.P. and A.K.R.; Data curation: S.B. and M.G.H.; Formal analysis: S.B. and M.G.H.; Funding acquisition: A.G.; Investigation: S.B., A.K.R., M.G.H. and A.K.P.; Methodology: S.B., A.K.R., M.G.H., A.K.P. and T.L.; Project administration: A.G. and S.B.; Visualization: A.G., S.B., A.K.R. and M.G.H.; Writing--original draft: S.B.; Writing--review & editing: S.B., A.K.R., M.G.H., A.G.

Additional Information
Competing Interests: Dr. Gulati is an employee of Pharmazz, Inc, he has issued and pending related patents. All other authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019

© The Author(s) 2019